ALNYLAM PHARMA
ALNYLAM PHARMA operates in Diversified Metals & Mining.
ALNYLAM PHARMA (DUL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 1.351x
Based on the latest financial reports, ALNYLAM PHARMA (DUL) has a cash flow conversion efficiency ratio of 1.351x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€43.71 Million) by net assets (€32.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ALNYLAM PHARMA - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how ALNYLAM PHARMA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ALNYLAM PHARMA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ALNYLAM PHARMA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prima Cakrawala Abadi PT
JK:PCAR
|
0.183x |
|
MICube Solution Inc
KQ:373170
|
0.050x |
|
Melkior Resources Inc
PINK:MKRIF
|
-0.097x |
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
N/A |
|
Bio-gate AG
XETRA:BIG1
|
N/A |
|
ATI Airtest Technologies Inc
PINK:AATGF
|
0.001x |
|
Chitose Internasional Tbk
JK:CINT
|
-0.045x |
|
Fly-E Group, Inc. Common Stock
NASDAQ:FLYE
|
-0.105x |
Annual Cash Flow Conversion Efficiency for ALNYLAM PHARMA (2016–2023)
The table below shows the annual cash flow conversion efficiency of ALNYLAM PHARMA from 2016 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €-220.64 Million | €104.16 Million | -0.472x | -113.80% |
| 2022-12-31 | €-158.22 Million | €-541.27 Million | 3.421x | +413.58% |
| 2021-12-31 | €588.20 Million | €-641.69 Million | -1.091x | -80.28% |
| 2020-12-31 | €1.02 Billion | €-614.96 Million | -0.605x | -212.68% |
| 2019-12-31 | €1.44 Billion | €-278.43 Million | -0.194x | +55.22% |
| 2018-12-31 | €1.30 Billion | €-562.62 Million | -0.432x | -99.41% |
| 2017-12-31 | €1.77 Billion | €-382.79 Million | -0.217x | +35.19% |
| 2016-12-31 | €920.22 Million | €-307.70 Million | -0.334x | -- |